CA2981945C - Antifungal 4-(4-(4-(((3r,5r)-5-((1 h-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl)piperazin-1-yl)-n-(2-hydroxycyclohexyl) benzamide, or a pharmaceutically acceptable salt thereof - Google Patents

Antifungal 4-(4-(4-(((3r,5r)-5-((1 h-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl)piperazin-1-yl)-n-(2-hydroxycyclohexyl) benzamide, or a pharmaceutically acceptable salt thereof Download PDF

Info

Publication number
CA2981945C
CA2981945C CA2981945A CA2981945A CA2981945C CA 2981945 C CA2981945 C CA 2981945C CA 2981945 A CA2981945 A CA 2981945A CA 2981945 A CA2981945 A CA 2981945A CA 2981945 C CA2981945 C CA 2981945C
Authority
CA
Canada
Prior art keywords
compound
treatment
methyl
pharmaceutically acceptable
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2981945A
Other languages
English (en)
French (fr)
Other versions
CA2981945A1 (en
Inventor
Thomas Christopher COLLEY
Kazuhiro Ito
Peter Strong
Mihiro Sunose
Matthew Mcconville
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pulmocide Ltd
Original Assignee
Pulmocide Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmocide Ltd filed Critical Pulmocide Ltd
Publication of CA2981945A1 publication Critical patent/CA2981945A1/en
Application granted granted Critical
Publication of CA2981945C publication Critical patent/CA2981945C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2981945A 2015-05-21 2016-05-20 Antifungal 4-(4-(4-(((3r,5r)-5-((1 h-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl)piperazin-1-yl)-n-(2-hydroxycyclohexyl) benzamide, or a pharmaceutically acceptable salt thereof Active CA2981945C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15168637.5 2015-05-21
EP15168637 2015-05-21
PCT/GB2016/051467 WO2016185225A1 (en) 2015-05-21 2016-05-20 Antifungal 4-(4-(4-(((3r,5r)-5-((1 h -1,2,4-triazol-1 -yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)- 3-methylphenyl)piperazin-1 -yl )-n -(2-h yd roxycyc lo h exyl) b e nzam i d e, or a pharmaceutically acceptable salt thereof.

Publications (2)

Publication Number Publication Date
CA2981945A1 CA2981945A1 (en) 2016-11-24
CA2981945C true CA2981945C (en) 2023-08-29

Family

ID=53267232

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2981945A Active CA2981945C (en) 2015-05-21 2016-05-20 Antifungal 4-(4-(4-(((3r,5r)-5-((1 h-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl)piperazin-1-yl)-n-(2-hydroxycyclohexyl) benzamide, or a pharmaceutically acceptable salt thereof

Country Status (16)

Country Link
US (3) US9969720B2 (enExample)
EP (1) EP3298006B1 (enExample)
JP (1) JP6811727B2 (enExample)
KR (1) KR102653821B1 (enExample)
CN (1) CN107635988B (enExample)
AU (1) AU2016263669B2 (enExample)
CA (1) CA2981945C (enExample)
DK (1) DK3298006T3 (enExample)
EA (1) EA032454B1 (enExample)
ES (1) ES2790723T3 (enExample)
HU (1) HUE048843T2 (enExample)
IL (1) IL254943B (enExample)
MX (1) MX379586B (enExample)
NZ (1) NZ735783A (enExample)
SG (1) SG11201708007VA (enExample)
WO (1) WO2016185225A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2790723T3 (es) * 2015-05-21 2020-10-29 Pulmocide Ltd Antifúngico 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-il)metil)-5-(2,4-difluorofenil)tetrahidrofurano-3-il)metoxi)-3-metilfenil)piperazina-1-il)-N -(2-hidroxiciclohexil)benzamida, o una sal farmacéuticamente aceptable del mismo
CN109329288A (zh) * 2018-11-09 2019-02-15 青岛农业大学 伏立康唑在制备用于防治植物病原菌的杀菌剂中的应用
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1292472C (en) 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
AU2811689A (en) 1987-11-20 1989-06-14 Schering Corporation Tri-and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
US5039676A (en) * 1990-05-11 1991-08-13 Schering Corporation Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
DK0736030T3 (da) * 1993-12-21 2001-10-29 Schering Corp Fungicide tetrahydrofuraner
US5714490A (en) 1993-12-21 1998-02-03 Schering Corporation Tetrahydrofuran antifungals
US5486625A (en) 1994-07-08 1996-01-23 Schering Corporation Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents
ES2199291T3 (es) 1995-06-02 2004-02-16 Schering Corporation Antifungicos de tetrahidrofurano.
EP0957101A1 (en) * 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
PL212985B1 (pl) 2001-04-03 2012-12-31 Schering Corp Ciekla zawiesina zawierajaca przeciwgrzybiczo skuteczna ilosc posakonazolu oraz zastosowanie zmikronizowanych czastek posakonazolu
EP1870405A1 (en) * 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
CN101402613B (zh) * 2008-11-14 2013-07-24 中国人民解放军第二军医大学 取代酚氧烷基胺三唑醇类抗真菌化合物及其制备方法
CN102234267A (zh) * 2010-04-21 2011-11-09 中国科学院上海药物研究所 新型三氮唑类抗真菌化合物、其药物组合物及其制备方法和用途
WO2013036866A1 (en) * 2011-09-07 2013-03-14 The Johns Hopkins University Itraconazole analogs and use thereof
WO2016087880A1 (en) 2014-12-05 2016-06-09 Pulmocide Limited Antimycotic compound
ES2790723T3 (es) * 2015-05-21 2020-10-29 Pulmocide Ltd Antifúngico 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-il)metil)-5-(2,4-difluorofenil)tetrahidrofurano-3-il)metoxi)-3-metilfenil)piperazina-1-il)-N -(2-hidroxiciclohexil)benzamida, o una sal farmacéuticamente aceptable del mismo

Also Published As

Publication number Publication date
MX2017014814A (es) 2018-02-15
AU2016263669B2 (en) 2020-04-30
IL254943A0 (en) 2017-12-31
CA2981945A1 (en) 2016-11-24
EA032454B1 (ru) 2019-05-31
CN107635988A (zh) 2018-01-26
MX379586B (es) 2025-03-11
NZ735783A (en) 2021-12-24
US10513511B2 (en) 2019-12-24
KR20180010189A (ko) 2018-01-30
JP6811727B2 (ja) 2021-01-20
US20180251453A1 (en) 2018-09-06
DK3298006T3 (da) 2020-03-30
KR102653821B1 (ko) 2024-04-02
US10280155B2 (en) 2019-05-07
EA201792558A1 (ru) 2018-05-31
IL254943B (en) 2021-01-31
EP3298006A1 (en) 2018-03-28
ES2790723T3 (es) 2020-10-29
WO2016185225A1 (en) 2016-11-24
US20170114047A1 (en) 2017-04-27
BR112017020807A2 (pt) 2018-07-03
CN107635988B (zh) 2021-06-18
HK1252779A1 (en) 2019-05-31
US9969720B2 (en) 2018-05-15
EP3298006B1 (en) 2020-01-01
US20190202813A1 (en) 2019-07-04
HUE048843T2 (hu) 2020-08-28
AU2016263669A1 (en) 2017-10-12
SG11201708007VA (en) 2017-12-28
JP2018520104A (ja) 2018-07-26

Similar Documents

Publication Publication Date Title
US11008307B2 (en) Compounds which are used in the preparation of the compound of formula (I)
US10513511B2 (en) Aqueous suspension formulation comprising 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluoro-phenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl) or a pharmaceutically acceptable salt thereof
HK1252779B (en) Antifungal 4-(4-(4-(((3r,5r)-5-((1 h -1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)- 3-methylphenyl)piperazin-1-yl )-n -(2-h yd roxycyc lo h exyl) b e nzam i d e, or a pharmaceutically acceptable salt thereof
BR112017020807B1 (pt) Composto 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-triazol-1-il)metil)-5-(2,4- difluorofenil)tetra-hidrofuran-3-il)metóxi)-3-metilfenil)piperazin-1-il)-n-(2- hidroxiciclo-hexil) benzamida antifúngica, seu processo de preparação, e composição farmacêutica
NZ730861B2 (en) Antimycotic compound
HK1244795B (en) Antimycotic compound

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210511

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250509

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250509

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260702